AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05510843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THB001
Description: 100 mg capsules for oral administration
Study NCT05795582 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: POPMETRE® (Axelife , France)
Description: Measurement with 2 devices
Study NCT06385808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTBF regimen
Description: The subjects will be treated with mitoxantrone hydrochloride liposome combined with thiotepa, busulfan and fludarabine as conditioning regimen prior to allo-HSCT.~Mitoxantrone hydrochloride liposome 24mg/m\^2 ivgtt d-7; Ctepide 5mg/kg ivgtt d-6\~-5; Busulfan 0.8mg/kg q6h ivgtt d-4\~-2; Fludarabine 50mg/m\^2 ivgtt d-4\~-2.
Study NCT06147895 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CVI-HBV-002
Description: Investigational Product
Study NCT05290350 — intervention group
Intervention type: OTHER
Intervention: OSA
Description: EXPOSURE TO OBSTRUCTIVE SLEEP APNEA
Study NCT05022680 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mhealth
Description: the peer-led intervention with mHealth technology (an application (APP) and Sports bracelet)
Study NCT06242626 — intervention group
Intervention type: OTHER
Intervention: observation
Description: analysis of clinical, laboratory and haemodynamics parameters
Study NCT06074055 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: FET Protocol
Description: Participants are randomized to either another programmed FET Protocol vs. a modified natural FET protocol
Study NCT05199597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.01% atropine
Description: 0.01%, room temp, Lab A
Study NCT05199597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.05% atropine
Description: 0.05%, room temp, Lab A
Study NCT05199597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.05% atropine
Description: 0.05%, refrigerated, Lab A
Study NCT05199597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.05% atropine
Description: 0.05%, room temperature, Lab B
Study NCT05787717 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Parental presence
Description: The parent is encouraged to stay close to their child and are given ample room on one side of the OR table for this purpose
Study NCT06314113 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Epigallocatechin Gallate
Description: Oral treatment with Epigallocatechin Gallate 200 mg per day
Study NCT06578494 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: Ultrasound-guided peripheral intravenous catheter insertion
Study NCT06578494 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Ultrasound-guided peripheral intravenous catheter insertion
Study NCT06576778 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PROVSIONALIZATION
Description: glass fiber composite as a temporary framework followed by PEKKTON definitive framework.
Study NCT06576778 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PROVSIONALIZATION
Description: glass fiber composite as a temporary framework followed by PEKKTON definitive framework.
Study NCT06578676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 MG
Description: PO, QD
Study NCT06578676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe/Rosuvastatin 10/10mg
Description: PO, QD
Study NCT06578676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 MG with Ezetimibe/Rosuvastatin 10/10mg
Description: PO, QD
Study NCT05740566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tarlatamab
Description: Tarlatamab will be administered as an IV infusion.
Study NCT05740566 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lurbinectedin
Description: Lurbinectedin will be administered per local SOC.
Study NCT05740566 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topotecan
Description: Topotecan will be administered per local SOC.
Study NCT05740566 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amrubicin
Description: Amrubicin will be administered per local SOC.
Study NCT05045638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Oral dose
Study NCT05045638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotorasib
Description: Oral dose
Study NCT04727190 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transbronchial Cryobiopsy
Description: The eligible patient will be randomized to TBCB group to receive transbronchial cryobiopsy.
Study NCT04727190 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transbronchial Forceps Biopsy
Description: The eligible patient will be randomized to TBFB group to receive transbronchial forceps biopsy.
Study NCT06576492 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RV4986A lotion
Description: * Application between Month -0.5 and Month 0 (before hair transplant): once a day on the entire scalp~* From 4 days after hair transplant and until Visit 4 (Month 0,5 post transplant): once a day on the recipient area~* Between Month 0.5 and Month 12: once a day on the entire scalp
Study NCT06576492 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: RD0057H shampoo
Description: * Application between Month -0.5 and Month 0 (before hair transplant): at usual frequency when required on the entire scalp~* From 2nd day after hair transplant and until the 7th day after hair transplant: application on the recipient area with a spray containing mixture of water and shampoo. For the rest of the head application with the same modalities than before hair transplant~* From the 8th day after hair transplant to the 15th day: application with a sponge on the recipient area~* From the 16th day after hair transplant and for the next 12th months: application with the same modalities than before hair transplant
Study NCT04390893 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasound
Description: Anesthesiologist would scan three planes of the neck to position the LMA
Study NCT04390893 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: air leakage test
Description: Anesthesiologist would use air leakage test to position the LMA
Study NCT04868734 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supportive Psychotherapy
Description: Supportive Psychotherapy give to patient with Acute Coronary Syndrome
Study NCT05942833 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sigmoid resection
Description: Timing of sigmoid resection
Study NCT05942833 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Sigmoid resection
Description: Timing of sigmoid resection
Study NCT05266157 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual lymph drainage
Description: Manual lymph drainage
Study NCT05266157 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: skin care, exercise and compression stocking
Study NCT05266157 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: skin care, exercise and compression stocking
Study NCT05474378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B7-H3CART
Description: B7-H3CART will be administered administered locoregionally (either ICV or both ICV and intratumorally (IT)) at one of the following doses:~Dose Level -1: 5 x 10\^6 CAR+ cells (+/- 20%) Dose Level 1: 10 x 10\^6 CAR+ cells (+/- 20%) Dose Level 2: 25 x 10\^6 CAR+ cells (+/- 20%) Dose Level 3: 50 x 10\^6 CAR+ cells (+/- 20%) Dose Level 4: 100 x 10\^6 CAR+ cells (+/- 20%)~B7-H3CART Dose Dose Level -1 (DL-1): 5 x 106 B7-H3CART+ cells (± 20%) Dose Level 1 (DL 1): 10 x 106 B7-H3CART+ cells (± 20%) Dose Level 2 (DL2): 25 x 106 B7-H3CART+ cells (± 20%) Dose Level 3 (DL3): 50 x 106 B7-H3CART+ cells (± 20%) Dose Level 4 (DL4): 100 x 106 B7-H3CART+ cells (± 20%)~Repeated every 28 days (-7 / +14 days) as long as infusion criteria are met for a total of 6 doses, with an option for an additional 6 doses, up to a total of 12.
Study NCT05845099 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Polymethyl Methacrylate-Based Complete Removable Dentures.
Description: The patients will receive Complete Removable Dentures processed by Heat cured acrylic resin.
Study NCT05845099 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photopolymerized Methacrylate- Based Complete Removable Dentures.
Description: The patients will receive a 3D-printed removable denture digitally manufactured using a 3d printer device with light polymerized resin.
Study NCT04827147 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multi-Periscopic Prism (MPP) glasses
Description: Spectacles with multi-periscopic prisms mounted as oblique peripheral prism segments
Study NCT04827147 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fresnel Peripheral Prism (FPP) glasses
Description: Spectacles with conventional permanent Fresnel prisms mounted as oblique peripheral prism segments
Study NCT06576492 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RD0057H shampoo
Description: * Application between Month -0.5 and Month 0 (before hair transplant): at usual frequency when required on the entire scalp~* From 2nd day after hair transplant and until the 7th day after hair transplant: application on the recipient area with a spray containing mixture of water and shampoo. For the rest of the head application with the same modalities than before hair transplant~* From the 8th day after hair transplant to the 15th day: application with a sponge on the recipient area~* From the 16th day after hair transplant and for the next 12th months: application with the same modalities than before hair transplant
Study NCT05647564 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: F-fluorodeoxyglucose positron emission tomography (FDG PET)
Description: Imaging scan
Study NCT05647564 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: prostate-specific membrane antigen positron emission tomography (PSMA PET)
Description: Imaging scan
Study NCT06329011 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Comprehensive rehabilitation therapy
Description: Including： Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training.
Study NCT06329011 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comprehensive rehabilitation therapy
Description: Including： Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training.
Study NCT06329011 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Intermittent Oro-esophageal Tube Feeding
Description: All patients are given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
Study NCT06329011 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Oro-esophageal Tube Feeding
Description: All patients are given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
Study NCT06335433 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Training (Isometric Handgrip Exercise)
Description: Participants allocated to the exercise groups will complete 6 weeks of isometric handgrip exercise training (IHGT) using an electronic hand dynamometer (Camry EH101, Zhongshan Camry Electronic Co. Ltd, Guangdong) for either 2 or 4 sessions per week. Each exercise session will consist of 4 x 2-minute isometric contractions at 30% MVC with 1 minute rest periods between contractions. The first bout will be performed on the dominant arm and then the arm will be alternated for each subsequent two-minute bout. Participants will be instructed to try keep the contraction tension as close as possible to the set tension of 30% MVC using visual feedback from the dynamometer's electronic display.
Study NCT05136820 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Atrial Flow Regulator
Description: Subjects will be randomized 1:1:1 where subjects will either receive the 6mm AFR device, 8mm AFR device or Sham procedure.
Study NCT06329011 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: In this study, transcranial direct current stimulation is performed using a battery-powered constant current stimulator. This device delivers the current through two electrodes immersed in saline solution. Specifically, a 50mm\*50mm anodal electrode pad is placed at the center of the healthy side swallowing sensory-motor cortex of the patient. According to the positioning method of the international 10-20 electrode system, the swallowing sensory-motor cortex of the left brain is located at the midpoint between C3 and T3, while that of the right brain is located at the midpoint between C4 and T4. The cathode is placed on the opposite shoulder, using a current of 1mA, once a day, for 20 minutes each time, and 5 days a week. The instruments used for placebo patients will not have any actual effect.
Study NCT06329011 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Transcranial direct current stimulation
Description: The Transcranial direct current stimulation will be performed without being turned on.
Study NCT05201170 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vehicle Ophthalmic Solution
Description: Ophthalmic Solution
Study NCT05201170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PL9643 Ophthalmic Solution
Description: Ophthalmic Solution
Study NCT05136820 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Atrial Flow Regulator
Description: Subjects will be randomized 1:1:1 where subjects will either receive the 6mm AFR device, 8mm AFR device or Sham procedure.
Study NCT05136820 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator
Description: Subjects will be randomized 1:1:1 where subjects will either receive the 6mm AFR device, 8mm AFR device or Sham procedure.
Study NCT06233682 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enriched environment
Description: In the experimental group (enriched environment), assistants will supervise participants sponatneoulsy engaging in activities, including listening to music, drawing, playing cards or board games, exercising the affected upper limb with constructions or puzzles, etc., in the living room and personal rooms. Posters and clocks will also aid in orientation and improve the physical environment.
Study NCT04788472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAR-T cells targeting CD19 and CD22
Description: Each subject receives sequential CD19 and CD22 CAR-T cells by intravenous infusion
Study NCT06230692 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: POWERbreathe Plus IMT
Description: Inspiratory muscle training will be performed using the POWERbreathe Plus IMT (POWERbreathe International Ltd., Warwickshire, UK), a commercially available inspiratory pressure threshold device. In this type of training, airflow is occluded until the generated inspiratory pressure reaches the predetermined threshold, which can be set at increments of 8 cm H2O.~During the first week of training, the target intensity will be set at 50% of baseline maximal inspiratory pressure (MIP.) During the second week, the target intensity will be set at 60% of baseline MIP. Beginning at the third week and for the remainder of the training program, the target intensity will be set at 75% of the participant's baseline MIP. The target volume will be 5 sets of 6 breaths per day (total of 30 breaths per day), separated by 1-minute rest breaks between sets. The frequency of training will be 5 days per week, for a duration of 6 weeks.
Study NCT05499117 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Light terapy
Description: Carex Day-Light Classic, Light intensity is white Light, 10000UX, and color temperature is 4000K
Study NCT05499117 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: pseudo-light therapy
Description: The pseudo-light stimulation group was red light with intensity less than 100lux
Study NCT05152433 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: E-BRAiN therapy
Description: The therapy system E-BRAiN is a purpose-built therapy system using a socially interactive humanoid robot and provides individualised therapy for arm rehabilitation based on the evidence-based therapies arm basis training, arm ability training, or mirror therapy for arm rehabilitation (paresis) or neurovisual training (neglect).
Study NCT05152433 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional therapy
Description: Conventional therapy specifies the neurorehabilitation therapy as applied as regular treatment.
Study NCT06584578 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole-Body Electromyostimulation
Description: Participants were included in tree exercise programs (Yoga, Pilates, WB-EMS) by an expert trainer 2 days a week for 12 weeks. At the same time, an active control group conducted a weekly diet counseling for 12 weeks by an expert dietician.
Study NCT06584578 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates
Description: Pilates exercise twice weekly for 12 weeks
Study NCT06584578 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tai Chi
Description: Pilates exercise twice weekly for 12 weeks
Study NCT06584578 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional counseling
Description: Nutritional counseling for 12 weeks
Study NCT06454799 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Akupressur
Description: The application will be carried out on 3 body points. These; Pericardium 6, Yintang and Shen men points. Acupressure will be applied to each of these acupressure points for 1 minute.
Study NCT05999344 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: commercially available cannabis administered prior to commercially available alcohol
Description: Self administration of cannabis prior to researcher administered alcohol
Study NCT05999344 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: commercially available alcohol administered prior to commercially available cannabis
Description: Researcher administered alcohol prior to self-administration of cannabis
Study NCT04929483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIO89-100
Description: Subcutaneous injection
Study NCT04929483 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection
Study NCT04929483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subcutaneous injection
Study NCT06149533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edoxaban
Description: Edoxaban, an oral selective factor Xa inhibitor, had been approved by the National Medical Products Administration in 2018. It is used for the treatment and recurrence prevention of deep venous thrombosis (DVT) and pulmonary embolism (PE) in adults.
Study NCT04198272 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CyberRwanda
Description: The CyberRwanda intervention consists of three primary components: 1. STORIES: The CyberRwanda curriculum empowers youth to learn about family planning and reproductive health and employment skills and to set goals for their futures through age-appropriate, interactive, digital and printed stories and activities. 2. LEARN: Q\&As and videos related to family planning and reproductive health. 3. SHOP: Youth can directly purchase health products, including menstrual hygiene and contraceptive products (emergency contraception, condoms, and oral contraceptive pills) online. The online health facility finder tool links youth to health facilities for longer-acting methods. All participating pharmacies will be trained to give unbiased, nonjudgmental information and services.